Correlation of the clinical progression with the degree and pattern of atrophy in patients with multiple sclerosis treated cladribine tablets

被引：0
|
作者：
Pogoda-Wesolowska, Aleksandra [1 ]
Aftyka, Joanna [2 ]
Zegadlo, Arkadiusz [3 ]
Staszewski, Jacek [1 ]
Stepien, Adam [1 ]
机构：
[1] Mil Inst Med, Natl Res Inst, Neurol Clin, Warsaw, Poland
[2] Warsaw Univ Technol, Fac Phys, Warsaw, Poland
[3] Mil Inst Med, Natl Res Inst, Dept Med Radiol, Warsaw, Poland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1871/4301
引用
收藏
页码：1252 / 1253
页数：2
相关论文
共 50 条
  • [1] Reduced Grey Matter Atrophy in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets
    Battaglini, Marco
    Sormani, Maria Pia
    Luchetti, Ludovico
    Gentile, Giordano
    Cortese, Rosa
    Alexandri, Nektaria
    De Stefano, Nicola
    NEUROLOGY, 2021, 96 (15)
  • [2] Reduced grey matter atrophy in patients with relapsing multiple sclerosis treated with cladribine tablets
    Battaglini, M.
    Sormani, M. P.
    Luchetti, L.
    Gentile, G.
    Cortese, R.
    Alexandri, N.
    De Stefano, N.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 231 - 231
  • [3] Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
    De Stefano, Nicola
    Giorgio, Antonio
    Battaglini, Marco
    De Leucio, Alessandro
    Hicking, Christine
    Dangond, Fernando
    Giovannoni, Gavin
    Sormani, Maria Pia
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : 222 - 226
  • [4] Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
    Moiola, Lucia
    Riva, Agostino
    Nicoletti, Ferdinando
    Uccelli, Antonio
    Salvetti, Marco
    Battistini, Luca
    Furlan, Roberto
    CURRENT NEUROPHARMACOLOGY, 2022, 20 (10) : 1811 - 1815
  • [5] Assessment of the impact of reconstitution therapies - cladribine tablets and alemtuzumab - on the atrophy progression among patients with multiple sclerosis
    Pogoda-Wesolowska, Aleksandra
    Stachura, Ignacy
    Maciagowska-Terela, Marzena
    Stepien, Adam
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1253 - 1253
  • [6] Low rate of progression independent of relapse in patients with relapsing multiple sclerosis treated with cladribine tablets
    De Stefano, Nicola
    Wiendl, Heinz
    Barkhof, Frederik
    Achiron, Anat
    Derfuss, Tobias
    Chan, Andrew
    Hodgkinson, Suzanne
    Prat, Alexandre
    Leocani, Letizia
    Schmierer, Klaus
    Sellebjerg, Finn
    Vermersch, Patrick
    Petit, Caroline
    Gardner, Lidia
    Montalban, Xavier
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 350 - 352
  • [7] Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study
    Rauma, Ilkka
    Viitala, Matias
    Kuusisto, Hanna
    Atula, Sari
    Sipila, Jussi O. T.
    Ryytty, Mervi
    Soilu-Hanninen, Merja
    Jarvinen, Elina
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 61
  • [8] COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update
    Jack, Dominic
    Damian, Doris
    Nolting, Axel
    Galazka, Andrew
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 51
  • [9] Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets
    Cortese, Rosa
    Battaglini, Marco
    Sormani, Maria Pia
    Luchetti, Ludovico
    Gentile, Giordano
    Inderyas, Maira
    Alexandri, Nektaria
    De Stefano, Nicola
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (01) : 179 - 186
  • [10] HEALTH STATE UTILITIES IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS TREATED WITH CLADRIBINE TABLETS
    Wong, S. L.
    Hohnhorst, P., V
    Hettle, R.
    Konings, P.
    VALUE IN HEALTH, 2017, 20 (09) : A725 - A725
12345